» Articles » PMID: 18981725

Targeting Cell Surface F1F0 ATP Synthase in Cancer Therapy

Overview
Specialties Oncology
Pharmacology
Date 2008 Nov 5
PMID 18981725
Citations 14
Authors
Affiliations
Soon will be listed here.
Citing Articles

Targeting of Ubiquitin E3 Ligase RNF5 as a Novel Therapeutic Strategy in Neuroectodermal Tumors.

Principi E, Sondo E, Bianchi G, Ravera S, Morini M, Tomati V Cancers (Basel). 2022; 14(7).

PMID: 35406574 PMC: 8997491. DOI: 10.3390/cancers14071802.


Defueling the cancer: ATP synthase as an emerging target in cancer therapy.

Wang T, Ma F, Qian H Mol Ther Oncolytics. 2021; 23:82-95.

PMID: 34703878 PMC: 8517097. DOI: 10.1016/j.omto.2021.08.015.


Potential Inhibitory Effect of 's Venom and of Its Two Main Components-Melittin and PLA-on FF-ATPase.

Nehme H, Ayde H, El Obeid D, Sabatier J, Fajloun Z Antibiotics (Basel). 2020; 9(11).

PMID: 33218209 PMC: 7699247. DOI: 10.3390/antibiotics9110824.


Multiomics Reveals Ectopic ATP Synthase Blockade Induces Cancer Cell Death via a lncRNA-mediated Phospho-signaling Network.

Chang Y, Hsu C, Tang C, Chen X, Huang H, Juan H Mol Cell Proteomics. 2020; 19(11):1805-1825.

PMID: 32788343 PMC: 7664121. DOI: 10.1074/mcp.RA120.002219.


Diverse Stakeholders of Tumor Metabolism: An Appraisal of the Emerging Approach of Multifaceted Metabolic Targeting by 3-Bromopyruvate.

Yadav S, Pandey S, Goel Y, Temre M, Singh S Front Pharmacol. 2019; 10:728.

PMID: 31333455 PMC: 6620530. DOI: 10.3389/fphar.2019.00728.